What do you see as the next big modality in biologics, and what factors are driving innovation in this space?
Antibody-drug conjugates (ADCs) have demonstrated great potential, particularly in oncology, with the ability to improve targeted treatment outcomes.
In a recent Pharma’s Almanac article, Samsung Biologics joined industry peers to share insights on the latest ADC advances ㅡ highlighting ongoing efforts to expand our offerings and deliver tailored services to clients through end-to-end capabilities.
Antibody-drug conjugates (ADCs) have demonstrated great potential, particularly in oncology, with the ability to improve targeted treatment outcomes.
In a recent Pharma’s Almanac article, Samsung Biologics joined industry peers to share insights on the latest ADC advances ㅡ highlighting ongoing efforts to expand our offerings and deliver tailored services to clients through end-to-end capabilities.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article